Dompe Farmaceutici S.p.A.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.8M
Doctors Paid
11
Transactions
3,243
2024 Total
$6.9M
Payment Breakdown by Category
Research$9.8M (99.9%)
Consulting$11,838 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.8M | 3,236 | 99.9% |
| Consulting Fee | $11,838 | 7 | 0.1% |
Payments by Type
Research
$9.8M
3,236 transactions
General
$11,838
7 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)" | $3.4M | 0 | 1,960 |
| A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO) | $2.5M | 4 | 103 |
| Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory Distress Syndrome (RESPIRATIO) | $1.6M | 0 | 958 |
| A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. | $1.0M | 0 | 141 |
| A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study) | $509,683 | 0 | 30 |
| A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Oxervate (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogrens dry eye disease (PROTEGO-1 study) | $358,454 | 0 | 17 |
| Recombinant Human Nerve Growth Factor Eye Drops for Management of Stage I Neurotrophic Keratitis | $175,214 | 0 | 15 |
| Hypotheia and the Incidence | $134,888 | 0 | 2 |
| A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. | $65,299 | 0 | 9 |
| IMAGO | $23,249 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Ophthalmology | $14,598 | 9 | $1,622 |
| Glaucoma Specialist | $2,250 | 1 | $2,250 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Unknown Provider | — | — | $8,315 | $0 |
| Alena Reznik, M.d, M.D | Ophthalmology | Newport Beach, CA | $2,400 | $0 |
| George Cioffi, Md, MD | Glaucoma Specialist | New York, NY | $2,250 | $0 |
| Dr. Roma Patel, M.d, M.D | Ophthalmology | Houston, TX | $2,250 | $0 |
| Dr. Ahmara Ross, M.d., Ph.d, M.D., PH.D | Ophthalmology | Philadelphia, PA | $2,250 | $0 |
| Giacomina Massaro-Giordano, Md, MD | Ophthalmology | Philadelphia, PA | $2,047 | $0 |
| Dr. Eric Mann, Md, MD | Ophthalmology | Dover, NJ | $1,732 | $0 |
| David Hardten, M.d, M.D | Ophthalmology | Minneapolis, MN | $1,313 | $0 |
| Dr. Melissa Toyos, Md, MD | Ophthalmology | Memphis, TN | $1,231 | $0 |
| Dr. John Sheppard, M.d, M.D | Ophthalmology | Norfolk, VA | $937.50 | $0 |
| Stephen Pflugfelder, M.d, M.D | Ophthalmology | Houston, TX | $437.50 | $0 |
About Dompe Farmaceutici S.p.A.
Dompe Farmaceutici S.p.A. has made $9.8M in payments to 11 healthcare providers, recorded across 3,243 transactions in the CMS Open Payments database. In 2024, the company paid $6.9M. The top product by payment volume is OXERVATE ($23,249).
Payments were distributed across 2 medical specialties. The top specialty by payment amount is Ophthalmology ($14,598 to 9 doctors).
Payment categories include: Consulting ($11,838), Research ($9.8M).